08:16 AM EST, 11/10/2025 (MT Newswires) -- Bicara Therapeutics ( BCAX ) reported a Q3 net loss Monday of $0.67 per diluted share, narrowing from a loss of $1.60 a year earlier.

Analysts surveyed by FactSet expected a loss of $0.54.

As of Sept. 30, the company had $407.6 million in cash and cash equivalents, which it said is expected to fund operations through H1 of 2029.

Shares of Bicara Therapeutics ( BCAX ) were up 2% in recent premarket activity.